A new study, published in
The drugs in question were glucagon-like peptide-1 receptor agonists (GLP-1RAs), like Ozempic and Wegovy, and sodium-glucose cotransporter-2 inhibitors (SGLT2is), like Jardiance.
Specifically, GLP-1RA was linked to a 33% lower risk of dementia, and SGLT2i was linked to a 43% lower risk. Other diabetes medications, however, were not associated with a change in risk.
As the average age of the population steadily rises, the number of dementia cases rises in step. Despite decades of intensive research, a cure remains elusive. Although some treatments can slow progress, we are far from a breakthrough.
